InvestSMART

Pharmaxis Ltd (ASX: PXS) - Announcements

- Current share price for PXS : $0.027

ASX company news and announcements for Pharmaxis Ltd (PXS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pharmaxis Ltd (PXS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pharmaxis Ltd (PXS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pharmaxis Ltd (PXS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Shareholder Update - March Quarter 2015 17 Apr 2015 8:41AM n/a $0.027 n/a
- Interim Results of Phase 1 Clinical Trial for PXS4728A 7 Apr 2015 8:27AM $0.130 $0.027 fallen by 79.23%
- Pharmaxis Signs with Boehringer Ingelheim for PXS4728A 12 Mar 2015 8:38AM $0.150 $0.027 fallen by 82%
- Half Yearly Report and Accounts 26 Feb 2015 5:20PM $0.135 $0.027 fallen by 80%
- Appendix 4C - quarterly 30 Jan 2015 12:56PM $0.100 $0.027 fallen by 73%
- Commencement of Phase 1 Clinical Trial for SSAO Inhibitor 21 Jan 2015 8:28AM n/a $0.027 n/a
- Commercialisation in US and NovaQuest Dispute Settled 24 Dec 2014 8:28AM $0.110 $0.027 fallen by 75.45%
- Appendix 4C - quarterly 30 Oct 2014 1:48PM $0.052 $0.027 fallen by 48.08%
- Phase 3 Clinical Trial in Cystic Fibrosis 30 Oct 2014 1:36PM $0.054 $0.027 fallen by 50%
- New data from B305 clinical trial presented at ERS 8 Sep 2014 11:43AM $0.055 $0.027 fallen by 50.91%
- Preliminary Final Report, Financial and Directors' Report 28 Aug 2014 10:38AM $0.056 $0.027 fallen by 51.79%
- SSAO Inhibitor Ready for the Clinic 28 Aug 2014 8:33AM $0.056 $0.027 fallen by 51.79%
- Pharmaxis Files Lawsuit Against NovaQuest 4 Aug 2014 10:01AM $0.058 $0.027 fallen by 53.45%
- Appendix 4C - quarterly 30 Jul 2014 4:32PM $0.064 $0.027 fallen by 57.81%
- Update On Timing Of Pre-Clinical Partnering Projects 8 Jul 2014 9:42AM $0.064 $0.027 fallen by 57.81%
- Communication from Financier NovaQuest 8 Jul 2014 9:37AM $0.064 $0.027 fallen by 57.81%
- Trading Halt 4 Jul 2014 10:07AM $0.077 $0.027 fallen by 64.94%
- Appendix 4C - quarterly 16 Apr 2014 4:39PM $0.091 $0.027 fallen by 70.33%
- Half Yearly Report and Accounts 19 Feb 2014 4:58PM $0.135 $0.027 fallen by 80%
- Appendix 4C - quarterly 30 Jan 2014 4:55PM $0.130 $0.027 fallen by 79.23%
- Scottish Medicines Consortium Accepts Bronchitol for CF Use 10 Dec 2013 3:15PM $0.125 $0.027 fallen by 78.40%
- Pharmaxis Elects to Receive Full NovaQuest Investment 30 Oct 2013 8:45AM $0.130 $0.027 fallen by 79.23%
- Appendix 4C - quarterly 16 Oct 2013 4:43PM $0.130 $0.027 fallen by 79.23%
- Pharmaxis Announces Delay to French Pricing for Bronchitol 29 Aug 2013 9:47AM $0.130 $0.027 fallen by 79.23%
- Preliminary Final Report 15 Aug 2013 10:52AM $0.155 $0.027 fallen by 82.58%

601 - 625 of 836 results

Page 25 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.